MaaT Pharma Third Quarter 2025 Financial Results and Financing Update

MaaT Pharma, a biotechnology company, presented its third-quarter financial results for 2025, reporting significant progress. The company highlighted a €10.5 million upfront payment from Clinigen after forming an exclusive license and distribution deal in July 2025. This agreement may enhance patient access to Xervyteg® (MaaT013) following its potential European Medicines Agency approval.

In October 2025, Maat Pharma accessed €3.5 million from the first tranche of a €37.5 million loan from the European Investment Bank. As of September 30, the company's cash and equivalents stood at €22.4 million, ensuring stability until February 2026. Revenues reached €3.4 million, marking a 45% year-over-year increase. These developments underscore MaaT Pharma's strategic funding efforts, ensuring the advancement of its clinical programs and shareholder value retention.